Matthew Sherman - Pulmatrix Insider

Pulmatrix Inc -- USA Stock  

USD 1.85  0.05  2.63%

Director

Dr. Matthew L. Sherman, M.D. serves as Director of the Company. Dr. Sherman has served as Chief Medical Officer of Acceleron Pharma, Inc. since May 2006 and as Executive Vice President Acceleron Pharma, Inc. since March 2015. Prior to joining Acceleron, he served as Senior Vice President and Chief Medical Officer at Synta Pharmaceuticals where he was responsible for clinical research, clinical operations, biostatistics, data management, regulatory affairs, quality assurance and program management. Prior to that, Dr. Sherman worked at Genetics Institute and Wyeth Pharmaceuticals in various capacities including Therapeutic Area Director for Oncology. While at Wyeth, Dr. Sherman provided senior oncology and hematology leadership for worldwide clinical development for both small molecule and biologic therapeutics, including the submission and approval of Mylotarg by the FDA. He has published numerous papers and book chapters in the field of oncology and clinical development and is named as an inventor of several patents. Dr. Sherman is board certified in Medical Oncology and Internal Medicine and held various clinical positions at Harvard Medical School with corresponding hospital appointments at the DanaFarber Cancer Institute and Brigham and Womens Hospital. Dr. Sherman received an SB in chemistry from the Massachusetts Institute of Technology and an M.D. from Dartmouth Medical School
Age: 60  Director Since 2016      
781-357-2333  http://www.pulmatrix.com
Sherman brings to the Board his medical background and extensive experience as a biopharmaceutical industry leader in clinical research and development.

Management Efficiency

The company has return on total asset (ROA) of (38.77) % which means that it has lost $38.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (122.79) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 4.55 M in liabilities with Debt to Equity (D/E) ratio of 28.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.95 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

John ThomasNantKwest Inc
2014
Sam ChawlaVBI Vaccines Inc
2014
William GarnerDel Mar Pharmaceuticals Inc
2013
Alan ColowickDimension Therapeutics Inc
2015
Alan RubinoVericel Corporation
2005
Steven GilmanVericel Corporation
2015
Trent DavisVBI Vaccines Inc
2014
Kate InmanVBI Vaccines Inc
2015
Richard KusserowNantKwest Inc
2014
Georges GemayelDimension Therapeutics Inc
2016
Erich MohrDel Mar Pharmaceuticals Inc
2017
Robert TothDel Mar Pharmaceuticals Inc
2013
Michael SteinmetzVBI Vaccines Inc
2014
Paul WottonVericel Corporation
2015
Jide ZeitlinVascular Biogenics Ltd
2008
Henry JiNantKwest Inc
N/A
Dennis BrownDel Mar Pharmaceuticals Inc
2013
Saiid ZarrabianDel Mar Pharmaceuticals Inc
2017
Frederick DriscollNantKwest Inc
2017
Ruth ArnonVascular Biogenics Ltd
2007
Alan TimminsVBI Vaccines Inc
2014

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 18 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Pulmatrix Inc to your portfolio

Top Management

Pulmatrix Inc Leadership Team
Terrance McGuire, Director, MBA
Matthew Sherman, Director
Alexander Klibanov, Founder
David Hava, Executive, Ph.D
Akihisa Akao, Director
Michael Higgins, Director, MBA
Steven Gillis, Director
Jean Sung, President
William Duke, CFO, MBA
David Maki, Director
Robert Clarke, CEO, Ph.D
Scott Rocklage, Director, Ph.D
Kurt Graves, Director
Richard Conley, Director, MBA
Mark Iwicki, Chairman, MBA
Amit Munshi, Director, MBA
Gregory French, Director
Hojabr Alimi, Chairman
Prof Edwards, Founder
David JD, Executive

Stock Performance

Pulmatrix Performance Indicators